Ablation of proximal tubular suppressor of cytokine signaling 3 enhances tubular cell cycling and modifies macrophage phenotype during acute kidney injury.
Nathan Susnik, Inga Sörensen-Zender, Song Rong, Sibylle von Vietinghoff, Xia Lu, Isabelle Rubera, Michel Tauc, Christine S Falk, Warren S Alexander, Anette Melk, Herrmann Haller, Roland Schmitt
Index: Kidney Int. 85(6) , 1357-68, (2014)
Full Text: HTML
Abstract
Suppressor of cytokine signaling 3 (SOCS-3) is an important intracellular negative regulator of several signaling pathways. We found that SOCS-3 is highly expressed in renal proximal tubules during acute kidney injury. To test the impact of this, conditional proximal tubular knockout mice (SOCS-3(sglt2Δ/sglt2Δ)) were created. These mice had better kidney function than their wild-type counterparts in aristolochic acid nephropathy and after ischemia/reperfusion injury. Kidneys of these knockout mice showed significantly more proximal tubular cell proliferation during the repair phase. A direct effect of SOCS-3 on tubular cell cycling was demonstrated by in vitro experiments showing a JAK/STAT pathway-dependent antimitotic effect of SOCS-3. Furthermore, acute damaged kidneys of the knockout mice contained increased numbers of F4/80(+) cells. Phenotypic analysis of these F4/80(+) cells indicated a polarization from classically activated to alternatively activated macrophages. In vitro, SOCS-3-overexpressing renal epithelial cells directly induced classical activation in cocultured macrophages, supporting the observed in vivo phenomenon. Thus, upregulation of SOCS-3 in stressed proximal tubules plays an important role during acute kidney injury by inhibition of reparative proliferation and by modulation of the macrophage phenotype. Antagonizing SOCS-3 could have therapeutic potential for acute kidney injury.
Related Compounds
Related Articles:
2014-08-30
[Oncotarget 5(16) , 6756-69, (2014)]
2014-01-01
[PLoS ONE 9(7) , e101824, (2014)]
2013-03-01
[Brain Behav. 3(2) , 75-88, (2013)]
2015-02-15
[J. Immunol. 194(4) , 1545-54, (2015)]
2015-04-01
[Neurotherapeutics 12(2) , 502-14, (2015)]